Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers ...

Dual long‑acting antibodies that lock RSV’s fusion protein from two sides protect against RSV A and B and prevent resistance, ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

The most common diagnoses among patients include schizophrenia, bipolar disorder and substance abuse.

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody ...

South Africa’s rollout of the twice-yearly HIV prevention injection lenacapavir could transform the fight against HIV, but ...

Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the ...

Chris Johnson built his football life on speed. He was the back who could turn a small opening into a sprint, a routine ...

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...

CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of ...